S&P 500   5,137.36 (+0.01%)
DOW   39,050.89 (-0.09%)
QQQ   445.17 (-0.10%)
AAPL   174.48 (-2.88%)
MSFT   416.24 (+0.18%)
META   502.86 (+0.11%)
GOOGL   132.66 (-3.27%)
AMZN   178.38 (+0.09%)
TSLA   188.70 (-6.88%)
NVDA   859.03 (+4.40%)
NIO   5.37 (-7.09%)
AMD   207.24 (+2.27%)
BABA   71.91 (-3.63%)
T   16.88 (-0.59%)
F   12.88 (+3.45%)
MU   96.59 (+1.51%)
CGC   3.02 (-5.92%)
GE   160.60 (+1.23%)
DIS   112.93 (+0.88%)
AMC   4.27 (-2.06%)
PFE   25.84 (-2.82%)
PYPL   59.39 (-1.90%)
XOM   104.19 (-1.56%)
S&P 500   5,137.36 (+0.01%)
DOW   39,050.89 (-0.09%)
QQQ   445.17 (-0.10%)
AAPL   174.48 (-2.88%)
MSFT   416.24 (+0.18%)
META   502.86 (+0.11%)
GOOGL   132.66 (-3.27%)
AMZN   178.38 (+0.09%)
TSLA   188.70 (-6.88%)
NVDA   859.03 (+4.40%)
NIO   5.37 (-7.09%)
AMD   207.24 (+2.27%)
BABA   71.91 (-3.63%)
T   16.88 (-0.59%)
F   12.88 (+3.45%)
MU   96.59 (+1.51%)
CGC   3.02 (-5.92%)
GE   160.60 (+1.23%)
DIS   112.93 (+0.88%)
AMC   4.27 (-2.06%)
PFE   25.84 (-2.82%)
PYPL   59.39 (-1.90%)
XOM   104.19 (-1.56%)
S&P 500   5,137.36 (+0.01%)
DOW   39,050.89 (-0.09%)
QQQ   445.17 (-0.10%)
AAPL   174.48 (-2.88%)
MSFT   416.24 (+0.18%)
META   502.86 (+0.11%)
GOOGL   132.66 (-3.27%)
AMZN   178.38 (+0.09%)
TSLA   188.70 (-6.88%)
NVDA   859.03 (+4.40%)
NIO   5.37 (-7.09%)
AMD   207.24 (+2.27%)
BABA   71.91 (-3.63%)
T   16.88 (-0.59%)
F   12.88 (+3.45%)
MU   96.59 (+1.51%)
CGC   3.02 (-5.92%)
GE   160.60 (+1.23%)
DIS   112.93 (+0.88%)
AMC   4.27 (-2.06%)
PFE   25.84 (-2.82%)
PYPL   59.39 (-1.90%)
XOM   104.19 (-1.56%)
S&P 500   5,137.36 (+0.01%)
DOW   39,050.89 (-0.09%)
QQQ   445.17 (-0.10%)
AAPL   174.48 (-2.88%)
MSFT   416.24 (+0.18%)
META   502.86 (+0.11%)
GOOGL   132.66 (-3.27%)
AMZN   178.38 (+0.09%)
TSLA   188.70 (-6.88%)
NVDA   859.03 (+4.40%)
NIO   5.37 (-7.09%)
AMD   207.24 (+2.27%)
BABA   71.91 (-3.63%)
T   16.88 (-0.59%)
F   12.88 (+3.45%)
MU   96.59 (+1.51%)
CGC   3.02 (-5.92%)
GE   160.60 (+1.23%)
DIS   112.93 (+0.88%)
AMC   4.27 (-2.06%)
PFE   25.84 (-2.82%)
PYPL   59.39 (-1.90%)
XOM   104.19 (-1.56%)
NASDAQ:DAWN

Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis

$17.09
-0.37 (-2.12%)
(As of 12:34 PM ET)
Today's Range
$16.66
$17.52
50-Day Range
$13.56
$17.46
52-Week Range
$9.67
$20.39
Volume
138,484 shs
Average Volume
454,758 shs
Market Capitalization
$1.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.60

Day One Biopharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
132.0% Upside
$40.60 Price Target
Short Interest
Bearish
16.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.11mentions of Day One Biopharmaceuticals in the last 14 days
Based on 49 Articles This Week
Insider Trading
Selling Shares
$562,860 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.60) to ($2.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.95 out of 5 stars

Medical Sector

831st out of 948 stocks

Pharmaceutical Preparations Industry

385th out of 441 stocks


DAWN stock logo

About Day One Biopharmaceuticals Stock (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

DAWN Stock Price History

DAWN Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals Inc
See More Headlines
Receive DAWN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/07/2023
Today
3/04/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DAWN
Fax
N/A
Employees
133
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.60
High Stock Price Target
$50.00
Low Stock Price Target
$34.00
Potential Upside/Downside
+132.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-142,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.97 per share

Miscellaneous

Free Float
79,695,000
Market Cap
$1.53 billion
Optionable
Optionable
Beta
-1.48
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Jeremy Bender M.B.A. (Age 52)
    Ph.D., CEO, President & Director
    Comp: $900k
  • Dr. Samuel C. Blackman M.D. (Age 55)
    Ph.D., Co-Founder and Head of R&D
    Comp: $651k
  • Mr. Charles N. York II (Age 47)
    COO, CFO & Secretary
    Comp: $715k
  • Dr. Mike Preigh Ph.D.
    Chief of Technology Operations
  • Mr. Adam Dubow (Age 57)
    General Counsel
  • Ms. Jaa Roberson
    Chief People Officer
  • Dr. Davy Chiodin Ph.D.
    Pharm.D., Chief Development Officer
  • Ms. Lauren Merendino M.B.A. (Age 48)
    Chief Commercial Officer
  • Prof. Raphael F. Rousseau M.D. (Age 55)
    Ph.D., Chief Medical Officer














DAWN Stock Analysis - Frequently Asked Questions

Should I buy or sell Day One Biopharmaceuticals stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DAWN shares.
View DAWN analyst ratings
or view top-rated stocks.

What is Day One Biopharmaceuticals' stock price target for 2024?

7 analysts have issued 1 year price objectives for Day One Biopharmaceuticals' shares. Their DAWN share price targets range from $34.00 to $50.00. On average, they expect the company's share price to reach $40.60 in the next year. This suggests a possible upside of 132.0% from the stock's current price.
View analysts price targets for DAWN
or view top-rated stocks among Wall Street analysts.

How have DAWN shares performed in 2024?

Day One Biopharmaceuticals' stock was trading at $14.60 at the beginning of the year. Since then, DAWN shares have increased by 19.9% and is now trading at $17.50.
View the best growth stocks for 2024 here
.

Are investors shorting Day One Biopharmaceuticals?

Day One Biopharmaceuticals saw a increase in short interest in February. As of February 15th, there was short interest totaling 9,720,000 shares, an increase of 6.2% from the January 31st total of 9,150,000 shares. Based on an average daily volume of 498,200 shares, the short-interest ratio is presently 19.5 days. Currently, 16.6% of the company's stock are short sold.
View Day One Biopharmaceuticals' Short Interest
.

When is Day One Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our DAWN earnings forecast
.

How were Day One Biopharmaceuticals' earnings last quarter?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) released its earnings results on Monday, August, 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.01.

What ETFs hold Day One Biopharmaceuticals' stock?

ETFs with the largest weight of Day One Biopharmaceuticals (NASDAQ:DAWN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

When did Day One Biopharmaceuticals IPO?

(DAWN) raised $126 million in an IPO on Thursday, May 27th 2021. The company issued 8,400,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Day One Biopharmaceuticals' major shareholders?

Day One Biopharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.48%), Franklin Resources Inc. (4.87%), Braidwell LP (4.84%), Price T Rowe Associates Inc. MD (2.66%), Price T Rowe Associates Inc. MD (2.66%) and Goldman Sachs Group Inc. (2.43%). Insiders that own company stock include Adam Dubow, Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant, Pharmaceutical Co Ltd Takeda, Samuel C Blackman, Venture Fund Xi LP Atlas and Xi LP Canaan.
View institutional ownership trends
.

How do I buy shares of Day One Biopharmaceuticals?

Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DAWN) was last updated on 3/4/2024 by MarketBeat.com Staff